The United Kingdom and the United States have reached a key trade agreement that will guarantee zero import taxes on British drug products entering the American market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to boost expenditure on drugs through the public health system. This commitment guarantees that duties on these crucial exports will remain at zero for a timeframe of 36 months.
This agreement is in response to recent statements to significantly raise duties on patented drug products, with potential rates floated up to double the cost.
"This arrangement between the UK strengthens the global environment for innovative medicines and establishes much-needed fairness to American-British drug exports," a statement said.
Trade Impact
Drugs represent one of the the United Kingdom's most significant exports to the United States, which is easily the largest destination for large UK drugmakers.
Statistics indicate that in the 12 months to the end of the third quarter, the UK exported drugs worth billions to the US. This value made up a significant portion of total UK exports in that period.
"This agreement protects work, stimulates investment and sets the stage for the UK to establish itself as a international leader for biotech and pharma," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement entails several notable pledges from the British government:
- Revised Affordability Limit: The UK will increase the cost ceiling at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a target to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The sum manufacturers must refund to the NHS to stay within budget will be limited at 15%. Last year, repayments exceeded 20%.
Industry Background
This agreement takes place against a long-running row between the drug companies and the ministers over medicine costs and approval rates.
This friction were intensified by claims that US customers were charged a premium for the equivalent treatments than patients in the Britain and the EU.
Recently, several major manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar expansions have been directed toward American operations.
The Science Minister publicly accepted that the NHS had to increase expenditure on medicines, noting that its expenditure on drugs had decreased as a share of its overall budget over the previous ten-year period.
